Epoetin alfa biosimilar - UBI Pharma

Drug Profile

Epoetin alfa biosimilar - UBI Pharma

Alternative Names: rhEPO - UBI Pharma; UB-851

Latest Information Update: 18 Mar 2016

Price : $50

At a glance

  • Originator UBI Pharma
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Anaemia

Most Recent Events

  • 14 Mar 2016 UBI Pharma plans a phase III trial for Anaemia (in patients with renal anaemia on hemodialysis) in Taiwan (IV) (NCT02708914)
  • 23 Feb 2016 Clinical trials in Anaemia in Taiwan (IV) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top